ACCESS TO INNOVATIVE AUTOIMMUNE THERAPIES IN LATIN AMERICA: CROSS-COUNTRY EVIDENCE TO INFORM VALUE-BASED DECISION-MAKING
Author(s)
Andre Ballalai, MSc1, OSCAR COURTNEY, BSc2, Francisca Rodriguez, MD3, Silvana Lay Ma, Eng., MBA4, Diego F. Guarin, MPH, MSc, MD4;
1IQVIA, New York, NY, USA, 2IQVIA, MEXICO, Mexico, 3cif chile, santiago, Chile, 4FIFARMA, MEXICO, Mexico
1IQVIA, New York, NY, USA, 2IQVIA, MEXICO, Mexico, 3cif chile, santiago, Chile, 4FIFARMA, MEXICO, Mexico
OBJECTIVES: To evaluate the availability and time to access of innovative autoimmune therapies in Latin America and support evidence-informed policy discussions on equitable access.
METHODS: Seventy-one innovative autoimmune medicines approved globally between 2014 and 2024 were assessed across ten countries. Availability and access timelines were standardized. Extended availability included full, limited, and private coverage. Data were gathered from industry associations, global companies, and public sources. Descriptive cross-country comparisons were performed.
RESULTS: Average extended availability was 17%. Argentina showed the highest availability (35%), while the Dominican Republic had the lowest (6%). Time to availability ranged from 17 to 51 months. The lack of comparable European datasets limits external benchmarking for autoimmune therapies.
CONCLUSIONS: Significant disparities in access to autoimmune treatments persist across Latin America. The findings highlight inefficiencies in regulatory and reimbursement pathways and underscore the need for collaborative reforms to improve timely and equitable access to high-value therapies.
METHODS: Seventy-one innovative autoimmune medicines approved globally between 2014 and 2024 were assessed across ten countries. Availability and access timelines were standardized. Extended availability included full, limited, and private coverage. Data were gathered from industry associations, global companies, and public sources. Descriptive cross-country comparisons were performed.
RESULTS: Average extended availability was 17%. Argentina showed the highest availability (35%), while the Dominican Republic had the lowest (6%). Time to availability ranged from 17 to 51 months. The lack of comparable European datasets limits external benchmarking for autoimmune therapies.
CONCLUSIONS: Significant disparities in access to autoimmune treatments persist across Latin America. The findings highlight inefficiencies in regulatory and reimbursement pathways and underscore the need for collaborative reforms to improve timely and equitable access to high-value therapies.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PT22
Topic
Health Policy & Regulatory
Topic Subcategory
Health Disparities & Equity, Reimbursement & Access Policy
Disease
SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)